New approaches to developing antimicrobials for resistant bacteria

Journal of Infection and Chemotherapy

Volumn 9, Issue 1, 2003, Pages 8-11

  Moellering Jr , Robert C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; ANTIINFECTIVE AGENT; ARSPHENAMINE; BACTENECTIN; CECROPIN; CEFTRIAXONE; CETHROMYCIN; DALBAVANCIN; DEFENSIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; KETOLIDE; MACROLIDE; MAGAININ DERIVATIVE; NATURAL PRODUCT; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; PLANT EXTRACT; PROTEGRIN; PROTEIN SYNTHESIS INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN; SULFONAMIDE; TEICOPLANIN DERIVATIVE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN DERIVATIVE; VERSICOR;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GENOMICS; HUMAN; REVIEW; SEAWEED;

EID: 0037368376     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-002-0213-7     Document Type: Review

References (21)

1. Moellering RC Jr. Past, present and future of antimicrobial agents. Am J Med 1995;99(Suppl 6A):11S-8S.
2. Kumazawa J, Yagisawa M. The history of antibiotics: the Japanese story. J Infect Chemother 2002;8:125-33.
3. Silver L, Bostian K. Screening of natural products for antimicrobial agents. Eur J Clin Microbiol Infect Dis 1990;9:455-671.
4. Sykes RB. The magic bullet in the new millennium: cause for optimism. J Infect Chemother 2002;8:121-4.
5. 21) as adjunctive treatment for children with severe meningococcal sepsis: a randomized trial. Lancet 2000;356:961-7.
6. Milatovic D, Schmitz F-J, Brisse S, Verhoef J, Fluit AC. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8796 clinical bacterial isolates. Antimicrob Agents Chemother 2000;44:1102-7.
7. Jones ME, Critchley IA, Karlowsky JA. Blosser-Middleton RS, Schmitz F-J, Thornsberry C, et al. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV. Antimicrob Agents Chemother 2002;46:1651-7.
8. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-44.
9. Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997;41:2165-72.
10. Douthwaite S, Champney WS. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother 2001;48:1-8.
11. Breithaupt H. The new antibiotics. Nature Biotechnol 1999;17: 1165-9.
12. Moir DT, Shaw KJ, Hare RS, Vovis GF. Genomics and antimicrobial drug discovery. Antimicrob Agents Chemother 1999;43:439-46.
13. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonos aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45: 105-16.
14. Finch RG, Pritchard DI, Bycroft BW, Williams P, Stewart GSAB. Quorum sensing: a novel target for anti-infective therapy. J Antimicrob Chemother 1998;42:569-71.
15. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Wennersten C, Venkataraman L, Novick RP, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002;46:1492-502.
16. Nguyen M, Quemard A, Broussy S, Bernadou J, Meunier B. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:2137-44.
17. Giglione C, Pierre M, Meinnel T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol 2000;36:1197-205.
18. Hackbarth CJ, Chen DZ, Lewis JG, Clark K, Mangold JB, Cramer JA, et al. N-Alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother 2002;46:2752-64.
19. Apfel CM, Locher H, Evers S, Takacs B, Hubschwerlen C, Pirson W, et al. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob Agents Chemother 2001;45:1058-64,
20. Torres Viera C, Tsiodras S, Gold HS, Coakley EPG, Wennersten C, Eliopoulos GM, et al. Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer. Antimicrob Agents Chemother 2001;45:973-5.
21. Summerton J. Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense and Nucleic Acid Drug Dev 1997;7:185-95.